



## **Disclosure according to Art. 111c (4) AktG (German Stock Corporation Act) - Disclosure of significant transactions with related persons**

### **Carl Zeiss Meditec AG signs lease agreement with Carl Zeiss, Inc., White Plains, NY, USA**

Jena, December 17, 2020

Carl Zeiss Meditec Inc., Dublin, CA, USA, a 100% subsidiary of Carl Zeiss Meditec AG (ISIN: DE0005313704), today has signed a long-term lease agreement for a new site at the Dublin, California, location as tenant with Carl Zeiss, Inc., White Plains, NY, USA, a 100% subsidiary of Carl Zeiss AG, which holds a total direct and indirect stake of approximately 59% in Carl Zeiss Meditec shares, as landlord.

The duration of the lease agreement is 10 years, starting on 01 January 2021. The annual base rent is approx. USD 5.7 million. The total value of the lease is approx. USD 62 million for the duration of 10 years and including a dynamic annual rent increase. The rented facilities will have a usable area of about 11,800 square meters.

In the opinion of the Management Board of Carl Zeiss Meditec AG, the terms of the new lease agreement are in line with standard market conditions on the basis of comparable local rents for commercial properties of a similar type, size, condition, development and location. The Management Board has evaluated standard market conditions on the basis of comprehensive documentation, in which rental conditions at the current location are compared with rental or leasing offers from third-party providers in the region, taking into account also planned expansion and development costs. Carl Zeiss Meditec Inc. currently employs more than 700 people at its Dublin site. A further increase in the number of employees is expected in the coming years and the new premises are designed to accommodate the company's strong growth.



## **Contact for investors and press**

Sebastian Frericks

Head of Investor Relations

Carl Zeiss Meditec AG

Tel.: +49 3641 220-116

E-Mail: [investors.meditec@zeiss.com](mailto:investors.meditec@zeiss.com)

### **Brief profile**

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 3,290 employees worldwide, the Group generated revenue of €1,335.5m in fiscal year 2019/20 (to 30 September).

The Group's head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain, France and Turkey. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG's shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world's leading groups in the optical and optoelectronic industries.

For further information visit: [www.zeiss.com/meditec](http://www.zeiss.com/meditec)